Discover 436 paid clinical trials in Edmonton, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Edmonton has a research history that most cities cannot match: the first successful islet cell transplant protocol for type 1 diabetes, known worldwide as the Edmonton Protocol, was developed at the University of Alberta in 2000 and changed transplant medicine. Diabetes studies are still a local strength, alongside cancer research at the Cross Cancer Institute, the comprehensive cancer centre for northern Alberta since 1968. Of the roughly 500 studies recruiting in the city, about a third are in oncology, with multiple myeloma and breast cancer among the most common, and the rest span inflammatory bowel disease, pulmonary hypertension, and sleep apnea.
Filter
2
Filter results
Results: 436
Does ESWT With BoNTA Treatment Improve Outcomes When Compared to Standard Management for Upper Limb Spasticity Patient.
for
Spasticity, Muscle
Location: Edmonton
Sponsor: University of Alberta
Sex: All
Age: 18 - 70+
Code: NCT05226637
Recruiting
Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System
for
Herpes Simplex
Location: Edmonton, Winnipeg, Stanford CA, San Diego CA,
Sponsor: National Center for Research Resources (NCRR)
Sex: All
Age: 0
Code: NCT00006132
Phase 3, Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
for
Pulmonary Arterial Hypertension
Location: Edmonton, Aurora CO, Kansas City KS, Santa Barbara CA,
Sponsor: Inhibikase Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07365332
Phase 3, Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
for
Facioscapulohumeral Muscular Dystrophy, FSHD,
Location: Edmonton, Calgary, Ottawa, Montreal
Sponsor: Avidity Biosciences, Inc.
Sex: All
Age: 16 - 70
Code: NCT07038200
Phase 3, Recruiting
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
for
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL,
Location: Edmonton
Sponsor: University of Alberta
Sex: All
Age: 2 - 70
Code: NCT03938987
Phase 1, Phase 2, Recruiting
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma